Question Bank › Skeptical premise dismantled with receipts

Skeptical premise dismantled with receipts

Skeptical premise dismantled with receipts: the call's central doubt is answered by named, checkable current facts

Calls Tested
497
Answered YES
24
Hit Rate
4.8%
rare by design

Biogen Inc. (BIIB) — this company's answers

NO on the Q2 2017 call 2017-07-25 B
The model's full reasoning — Q2 2017 call → NO我们根据提供的财报电话会议记录,判断是否存在一个明确的、公司特有的疑虑,并且管理层用已发生的、可核查的事实直接反驳了该疑虑。 首先,寻找疑虑。分析师的问题中,有关于临床风险(Geoff Meacham)、资本配置(Eric Schmidt)、长期增长(Umer Raffat)、SPINRAZA市场(Ronny Gal、Robyn Karnauskas)、MS竞争(Ying Huang)等。但最突出的疑虑是关于SPINRAZA的渗透率,特别是Type 2患者因脊柱手术难以接受鞘内注射的问题。管理层(Michel和Al)直接承认了这一点,并给出了具体数据:60%的Type 2患者有脊柱手术史,但同时也指出他们正在努力解决,并提到波士顿儿童医院等中心正在建立流程。然而,管理层并没有用已发生的、可核查的运营事实来反驳这个疑虑,而是承认挑战并说明正在努力。这更像是承认疑虑而非反驳。 另一个可能的疑虑是MS业务面对竞争(如OCREVUS)的韧性。Michel提到TYSABRI受到压力,但强调其疗效和患者忠诚度,并提到市场增长。但这里没有具体的、已发生的可核查事实来反驳,更多是观点和预期。 关于资本配置,管理层表示将优先投资增长而非回购,但也没有用具体事实反驳疑虑。 最接近的可能是关于SPINRAZA的疑虑,但管理层的回应是承认困难并说明正在解决,没有提供已实现的、可核查的相反事实(如患者数量增长、收入增长等)。虽然提到了收入增长,但那是整体业绩,不是针对疑虑的直接反驳。 因此,没有找到明确的、公司特有的疑虑被管理层用已发生的具体事实直接反驳的动态。管理层更多是承认挑战并表达信心。 所以答案应为NO。

← Back to the full BIIB analysis

Show the exact prompt the model was given
Using ONLY the supplied earnings call transcript and no outside information: On this call, is there ONE IDENTIFIABLE DOUBT ABOUT THIS COMPANY THAT IS LIVE IN THE CONVERSATION — evident because analysts press it, or because management itself names it as what skeptics or the market believe — AND does management answer that specific doubt NOT with reassurance, plans, or argument, but with NAMED, CHECKABLE FACTS FROM THE RECENT PERIOD that run directly against it — concrete events, behaviors, or numbers already realized (customers renewed or expanded when expected to leave, demand that held or grew through the feared window, losses that narrowed from operations, the doubted product performing in real use, the feared dependency reduced by actual new business) — described specifically enough that a reader could later verify them, with management conveying that the same contrary evidence is continuing rather than a one-quarter fluke? Answer YES when both halves come through as one dynamic in the transcript, in whatever form fits the business: a genuine, company-specific standing doubt, and a rebuttal built from already-occurred operating facts that the doubt's holders could check. It strengthens a YES when management engages the doubt directly and calmly rather than deflecting, and when the facts offered are of a kind that will keep accruing. Answer NO if no company-specific doubt is visible — an ordinary healthy company fielding routine questions. NO if the doubt exists but the answer is chiefly confidence, vision, targets, or projections. NO if the period's evidence actually confirms the doubt and management is excusing it. NO if the contrary facts are one-time items (asset sales, settlements, financings) rather than operating substance. NO if the doubt is generic macro gloom not attached to this company. NO if the rebuttal facts are vague ('demand remains strong') without specific grounding. NO if the dynamic appears only in an analyst's characterization that management does not itself engage with substance. Use only the supplied transcript. Answer only YES or NO.

Companies that answered YES

TickerCompanyCallDateCall grade
GL Globe Life Inc. Q1 2024 2024-04-23 F
MET MetLife, Inc. Q4 2023 2024-02-01 B+
SITM SiTime Corporation Q2 2023 2023-08-02 C+
PGRE Paramount Group, Inc. Q2 2023 2023-08-01 D
MBLY Mobileye Global Inc. Q2 2023 2023-07-28 B+
CRBG Corebridge Financial, Inc. Q4 2022 2023-02-22 B
UAL United Airlines Holdings, Inc. Q4 2022 2023-01-18 B
CRL Charles River Laboratories International Q2 2022 2022-08-03 C
LIN Linde plc Q2 2022 2022-07-28 B+
CME CME Group Inc. Q2 2022 2022-07-27 B
BFIN BankFinancial Corporation Q1 2022 2022-05-06 A
BXP Boston Properties, Inc. Q1 2022 2022-05-03 A
VVV Valvoline Inc. Q1 2022 2022-02-09 C+
IPGP IPG Photonics Corporation Q3 2021 2021-11-02 C
AMC AMC Entertainment Holdings, Inc. Q2 2021 2021-08-09 D
ESRT Empire State Realty Trust, Inc. Q2 2021 2021-07-29 C+
T AT&T Inc. Q3 2018 2018-10-24 C+
AVT Avnet, Inc. Q2 2018 2018-01-25 B
PII Polaris Inc. Q3 2017 2017-10-24 C+
GNTX Gentex Corporation Q3 2017 2017-10-20 B
CCOI Cogent Communications Holdings, Inc. Q2 2017 2017-08-03 B
TGI Triumph Group, Inc. Q2 2017 2016-11-03 C+
HPP Hudson Pacific Properties, Inc. Q4 2015 2016-02-25 C
SAN Banco Santander, S.A. Q4 2015 2016-01-27 B

How the model reasoned

IPGP · Q3 2021 → YESThe question is very specific: Is there ONE IDENTIFIABLE DOUBT ABOUT THIS COMPANY THAT IS LIVE IN THE CONVERSATION, and does management answer it with NAMED, CHECKABLE FACTS FROM THE RECENT PERIOD tha...YES The transcript shows a clear, company-specific doubt centered on China market softness and competitive pricing pressure, which analysts repeatedly press (e.g., on whether gross margins will hold, if diversification will offset the impact, and whether LightWELD can scale). Management directly engages this doubt by citing concrete, checkable facts from 2022: China revenue down only 7% while North America grew +55% and Europe +50%, gross margin expanded 100 bps to 49% driven by product mix and pricing discipline, and other China applications (EV battery, additive manufacturing, marking) remained robust.
CRBG · Q4 2022 → YESThe question is very specific: Is there ONE IDENTIFIABLE DOUBT ABOUT THIS COMPANY THAT IS LIVE IN THE CONVERSATION, and does management answer it with NAMED, CHECKABLE FACTS FROM THE RECENT PERIOD tha...YES The transcript shows a clear, company-specific doubt about elevated fixed annuity surrenders in a rising-rate environment, which analysts press and management itself flags as expected for 2023.
GL · Q1 2024 → YESThe question is: Is there ONE IDENTIFIABLE DOUBT ABOUT THIS COMPANY THAT IS LIVE IN THE CONVERSATION, and does management answer that specific doubt with NAMED, CHECKABLE FACTS FROM THE RECENT PERIOD ...

More from the question bank

Profit machinery upgraded while volume stillNew chapter with early proofDemand has broadened across independent fronExternal validators convergingOperator fluency on fresh groundThe bottleneck is inside and being paid awayAll questions →
Not investment advice. Artul.ai publishes AI-generated earnings-call quality grades and expected-volatility estimates — never buy or sell recommendations. We tested over 1,600 predictive hypotheses against 165,000 transcripts; the honest result, including what failed, is documented in our methodology.